Early B-cell factor 1 (EBF1)

Early B-cell factor 1 (EBF1) is a highly conserved transcription factor essential for B-lymphocyte differentiation and lineage commitment[1][2]. It belongs to the COE/EBF family, containing a unique DNA-binding domain, a transcription factor immunoglobulin (TIG/IPT) domain, an HLH dimerization motif, and a C-terminal transactivation domain[1]. EBF1 acts as a "pioneer factor," binding naïve chromatin and establishing accessibility for lineage-specific gene activation in B cells, often by recruiting the BRG1 subunit of the SWI/SNF chromatin-remodeling complex[2]. Its occupancy is required for maintenance of B cell gene expression and repression of alternative lineage genes. In addition to hematopoietic tissues, EBF1 regulates adipocyte and sensory neuron differentiation. Disrupted EBF1 activity leads to developmental arrest in B-cell progenitors and has emerging links to tumor suppression in various contexts[1]. EBF1 is not currently the direct target of approved drugs, but its molecular network represents a critical node in research on immunodeficiency, cell fate reprogramming, and cancer biology. Monitoring EBF1 activity and expression is pivotal in cell lineage tracing and disease diagnostics.

Other names

Transcription factor COE1COE1EBFO/E-1OE-1OLF1Collier, Olf and EBF transcription factor 1Early B cell factor 1Olfactory neuronal transcription factor 1

There are no drugs with well-characterized mechanisms of action targeting EBF1. Therapeutic approaches that modulate EBF1 (such as gene therapy or small molecules that affect upstream or downstream regulatory pathways) are investigational.